EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• EGFR-activating mutations are common in lung adenocarcinoma.
• Resistance to EGFR tyrosine kinase inhibitors (TKIs) can occur via small cell lung cancer (SCLC) transformation in about 5% of patients.
• The molecular basis and poor outcomes of EGFR-mutant SCLC post-transformation are not well understood.

Purpose of the Study:

• To establish and characterize EGFR-mutant SCLC cell lines derived from lung adenocarcinoma.
• To investigate the molecular basis of these transformed SCLC cells.
• To explore potential therapeutic strategies for improved patient outcomes.

Main Methods:

• Established two EGFR-mutant SCLC cell lines from lung adenocarcinoma patients post-EGFR-TKI failure.
• Analyzed genomic alterations using array-based comparative genomic hybridization.
• Assessed gene expression via RNA microarray, focusing on EGFR, mesenchymal, and neuroendocrine markers.
• Evaluated therapeutic efficacy of combined EGFR-TKI and AKT inhibitor, and histone deacetylase inhibitors in vitro and in vivo.

Main Results:

• Two distinct SCLC phenotypes (suspensive and adherent) were observed, sharing genomic alterations.
• Adherent cells showed increased EGFR and mesenchymal markers, with decreased neuroendocrine markers.
• RNA microarray revealed a unique gene expression pattern distinct from NSCLC and classical SCLC.
• Combined EGFR-TKI and AKT inhibition reduced cell viability; histone deacetylase inhibitors significantly inhibited cell viability in vitro and in vivo.

Conclusions:

• EGFR-mutant SCLC represents a distinct subclass characterized by epithelial-mesenchymal transition phenotypes.
• Combination therapies including AKT or histone deacetylase inhibitors may offer therapeutic options for transformed EGFR-mutant SCLC.